Walleye Trading
PTGX icon

Walleye Trading’s Protagonist Therapeutics PTGX Stock Holding History

Walleye Trading’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-105,360
Closed -$2.64M – 5106
2023
Q1 		$2.42M Buy
105,360
+55,851
+113% +$938K 0.01% 1541
2022
Q4 		$540K Buy
+49,509
New +$418K ﹤0.01% 2746
2018
Q4 		– Sell
-27,608
Closed -$284K – 5172
2018
Q3 		$284K Buy
27,608
+5,243
+23% +$45.1K ﹤0.01% 3439
2018
Q2 		$150K Buy
+22,365
New +$172K ﹤0.01% 3820

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Walleye Trading's PTGX Position: Q2 2023 in Review

Walleye Trading sold out of Protagonist Therapeutics (PTGX) in Q2 2023, closing a stake of 105,360 shares — an estimated $2.64M sold.

Walleye Trading first reported a position in PTGX in Q2 2018 and held it in 4 quarters. The position peaked at $2.42M in Q1 2023. 167 funds tracked by Wall St. Rank hold PTGX as of Q2 2023.

  • Walleye Trading reported no remaining Protagonist Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Walleye Trading sold 105,360 Protagonist Therapeutics shares in Q2 2023, an estimated $2.64M.
  • Walleye Trading first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 4 quarters.
  • Walleye Trading's Protagonist Therapeutics position peaked at $2.42M in Q1 2023.
  • 167 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2023.

Based on Walleye Trading's 13F filing for Q2 2023, filed 14 Aug 2023.